drugset / Trial / NCT00614380

Open Label Study Telmisartan and Amlodipine in Hypertension

NCT00614380

Phase 3 Completed 976 enrolled Boehringer Ingelheim
Treatment

Summary

The primary objective of this trial is to assess the efficacy and safety of the fixed dose combinations telmisartan 40 mg / amlodipine 5 mg (T40/A5) or telmisartan 80 mg / amlodipine 5 mg (T80/A5) during long-term open-label treatment.

Timeline

Start
2008-01
Primary completion
2009-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject Telmisartan Other / unclassified 40 mg
Subject Telmisartan Other / unclassified 80 mg

Indications